| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
1 From the Department of Ophthalmology, University of Innsbruck; and the 2 Laboratory of Psychiatry, Department of Psychiatry, University of Innsbruck, Austria.
PURPOSE. To help further define the possible role of vascular endothelial growth factor (VEGF) in the pathogenesis of corneal neovascularization, the expression of VEGF and of its receptors Flt-1 and Flk-1 was investigated in various inflammatory corneal diseases.
METHODS. Polyclonal antibodies to VEGF and its receptors were used for immunohistochemical staining of frozen sections of 38 human corneas with various degrees of neovascularization and inflammation. In addition, a panel of monoclonal antibodies was used to characterize the composition of the inflammatory infiltrates and to confirm the presence of neovascularization. Furthermore, VEGF concentrations were determined in vascularized corneas using a sensitive enzyme-linked immunosorbent assay.
RESULTS. VEGF was expressed by epithelial cells, by corneal endothelial cells, by vascular endothelial cells of limbal vessels and of newly formed vessels in the stroma, and weakly by keratocytes. Furthermore, VEGF expression was often markedly increased in inflamed corneas on epithelial cells and on vascular endothelial cells, particularly in the vicinity of macrophage infiltrates, and on fibroblasts in scar tissue. Correspondingly, VEGF concentrations were significantly higher in vascularized corneas compared with normal control corneas (P < 0.001). Expression of both VEGF receptors, Flt-1 and Flk-1, was increased on endothelial cells of newly formed vessels in the stroma of inflamed corneas compared with limbal vessels of normal control corneas. In addition, Flt-1 was also expressed by corneal endothelial cells and by macrophages, whereas Flk-1 expression was lacking.
CONCLUSIONS. These results demonstrate that VEGF, Flt-1, and Flk-1 are strongly expressed in inflamed and vascularized human corneas and, thus, may play an important role in corneal neovascularization.
This article has been cited by other articles:
|
|
 |
|
  P.-H. Chu, L.-K. Yeh, H.-C. Lin, S.-M. Jung, D. H.-K. Ma, I-J. Wang, H.-H. Wu, T.-F. Shiu, and J. Chen Deletion of the FHL2 Gene Attenuating Neovascularization after Corneal Injury Invest. Ophthalmol. Vis. Sci., December 1, 2008; 49(12): 5314 - 5318. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. J. Divito and R. L. Hendricks Activated Inflammatory Infiltrate in HSV-1-Infected Corneas without Herpes Stromal Keratitis Invest. Ophthalmol. Vis. Sci., April 1, 2008; 49(4): 1488 - 1495. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. J. DeStafeno and T. Kim Topical Bevacizumab Therapy for Corneal Neovascularization Arch Ophthalmol, June 1, 2007; 125(6): 834 - 836. [Full Text] [PDF]
|
|
|
|
 |
|
 R. P A Manzano, G. A Peyman, P. Khan, P. E Carvounis, M. Kivilcim, M. Ren, J. C Lake, and P. Chevez-Barrios Inhibition of experimental corneal neovascularisation by bevacizumab (Avastin) Br. J. Ophthalmol., June 1, 2007; 91(6): 804 - 807. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Aghi, S. D. Rabkin, and R. L. Martuza Angiogenic Response Caused by Oncolytic Herpes Simplex Virus-Induced Reduced Thrombospondin Expression Can Be Prevented by Specific Viral Mutations or by Administering a Thrombospondin-Derived Peptide Cancer Res., January 15, 2007; 67(2): 440 - 444. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Cursiefen, L. Chen, M. Saint-Geniez, P. Hamrah, Y. Jin, S. Rashid, B. Pytowski, K. Persaud, Y. Wu, J. W. Streilein, et al. Nonvascular VEGF receptor 3 expression by corneal epithelium maintains avascularity and vision PNAS, July 25, 2006; 103(30): 11405 - 11410. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Dell, S. Peters, P. Muther, N. Kociok, and A. M. Joussen The Role of PDGF Receptor Inhibitors and PI3-Kinase Signaling in the Pathogenesis of Corneal Neovascularization Invest. Ophthalmol. Vis. Sci., May 1, 2006; 47(5): 1928 - 1937. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Ueno, B. L. Lyons, L. M. Burzenski, B. Gott, D. J. Shaffer, D. C. Roopenian, and L. D. Shultz Accelerated Wound Healing of Alkali-Burned Corneas in MRL Mice Is Associated with a Reduced Inflammatory Signature Invest. Ophthalmol. Vis. Sci., November 1, 2005; 46(11): 4097 - 4106. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Ma, P. Ottino, H. E. P. Bazan, and N. G. Bazan Platelet-Activating Factor (PAF) Induces Corneal Neovascularization and Upregulates VEGF Expression in Endothelial Cells Invest. Ophthalmol. Vis. Sci., September 1, 2004; 45(9): 2915 - 2921. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Usui, S. Ishida, K. Yamashiro, Y. Kaji, V. Poulaki, J. Moore, T. Moore, S. Amano, Y. Horikawa, D. Dartt, et al. VEGF164(165) as the Pathological Isoform: Differential Leukocyte and Endothelial Responses through VEGFR1 and VEGFR2 Invest. Ophthalmol. Vis. Sci., February 1, 2004; 45(2): 368 - 374. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. McMorran, L. Town, E. Costelloe, J. Palmer, J. Engel, D. Hume, and B. Wainwright Effector ExoU from the Type III Secretion System Is an Important Modulator of Gene Expression in Lung Epithelial Cells in Response to Pseudomonas aeruginosa Infection Infect. Immun., October 1, 2003; 71(10): 6035 - 6044. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. K. Ambati, A. Anand, A. M. Joussen, W. A. Kuziel, A. P. Adamis, and J. Ambati Sustained Inhibition of Corneal Neovascularization by Genetic Ablation of CCR5 Invest. Ophthalmol. Vis. Sci., February 1, 2003; 44(2): 590 - 593. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Joussen, V. Poulaki, N. Mitsiades, S. U. Stechschulte, B. Kirchhof, D. A. Dartt, G.-H. Fong, J. Rudge, S. J. Wiegand, G. D. Yancopoulos, et al. VEGF-Dependent Conjunctivalization of the Corneal Surface Invest. Ophthalmol. Vis. Sci., January 1, 2003; 44(1): 117 - 123. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C Cursiefen, C Hofmann-Rummelt, M Kuchle, and U Schlotzer-Schrehardt Pericyte recruitment in human corneal angiogenesis: an ultrastructural study with clinicopathological correlation Br. J. Ophthalmol., January 1, 2003; 87(1): 101 - 106. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
